RO INTEGRATES WITH NOVOCARE® PHARMACY TO PROVIDE SEAMLESS ACCESS TO WEGOVY® AT THE LOWEST CASH PRICE
A first-of-its-kind integration means patients never have to leave the Ro app to get the most affordable, FDA-approved GLP-1 medication from Novo Nordisk shipped directly to their door
NEW YORK, April 29, 2025 /PRNewswire/ -- Ro today announced an integration with NovoCare® Pharmacy to provide seamless access to all doses of Wegovy® at the best available cash price of $499 per month. By working directly with Novo Nordisk's direct-to-patient option NovoCare® Pharmacy, Ro ensures patients have a reliable supply of FDA-approved GLP-1 medication directly from the manufacturer. With Ro's streamlined experience, patients can consult with a provider and get access to effective GLP-1 medication at the lowest cash price, without ever having to leave the Ro app.
'Fighting for patients means making it as easy and affordable as possible to access high-quality treatment, and that's exactly what integrating with NovoCare® Pharmacy offers patients,' said Zach Reitano, co-founder and CEO of Ro. 'Adding Novo Nordisk's FDA-approved treatments at the best available cash price will help more patients nationwide get the obesity care they need to achieve their goals, particularly those without insurance coverage.'
Ro makes it easy for patients to achieve their health goals by vertically integrating telehealth, lab and pharmacy services all onto one platform. With the Body Membership, patients have access to high-quality, obesity care including: access to a licensed physician, 24/7 messaging, 1-1 coaching, educational content, weight tracking and dose logging, labs, side-effect monitoring, and monthly check-ins to handle everything from dose titration to counseling.
This integration adds to Ro's obesity care formulary, already one the most comprehensive of any telehealth company, integrating cash pay and insurance eligible options that can be picked up at a retail pharmacy or delivered. With the Ro Insurance Checker, anyone can verify their benefits coverage for free and find the best possible medication choice at the lowest possible price – whether that's using insurance coverage or paying cash. To date, Ro has helped hundreds of thousands of people understand their benefits coverage to get the best medication for them.
Since its founding, Ro has invested in its direct-to-patient model designed to give patients nationwide more affordable, easier access to high-quality care. By integrating with NovoCare® Pharmacy, Ro is scaling high-quality care for the most common chronic condition in the U.S. at a fraction of the cost. CenterWell Pharmacy is the dispensing pharmacy managing prescription fulfilment and delivery for NovoCare® Pharmacy.
About Ro
Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the easiest, most effective care possible. Ro is the only company to offer nationwide telehealth, labs, and pharmacy services. This is enabled by Ro's vertically integrated platform that helps patients achieve their goals through a convenient, end-to-end healthcare experience spanning from diagnosis, to delivery of medication, to ongoing care. Since 2017, Ro has helped millions of patients, including one in every county in the United States, and in 98% of primary care deserts.
Contact: [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/ro-integrates-with-novocare-pharmacy-to-provide-seamless-access-to-wegovy-at-the-lowest-cash-price-302441159.html
SOURCE Ro
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
HIMS Stock To $25?
CANADA - 2025/03/31: In this photo illustration, the Hims & Hers Health logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Hims & Hers Health (NASDAQ: HIMS) experienced a devastating 35% stock crash on June 23, 2025, after Novo Nordisk abruptly terminated their brief partnership. The dramatic sell-off reflects not just the immediate loss of a key business relationship, but fundamental questions about the company's long-term viability in the weight-loss drug market. If you want upside with a smoother ride than an individual stock, consider the High Quality portfolio, which has outperformed the S&P and clocked >91% returns since inception. On a separate note, see – Is Iran Bluffing While Readying An Attack? The Partnership That Wasn't The collaboration between HIMS and Novo Nordisk, which began in April 2025, was supposed to be a game-changer for the telehealth company. The partnership promised direct access to Wegovy, Novo Nordisk's blockbuster weight-loss drug, through HIMS's platform. This arrangement had fueled much of HIMS's remarkable 150% stock surge earlier this year, as investors bet on a clear pathway to sustained revenue growth. However, the partnership lasted barely two months. Novo Nordisk cited concerns over what it called "illegal mass compounding and deceptive marketing" by HIMS, specifically pointing to the company's continued sales of personalized, compounded versions of semaglutide (Wegovy's active ingredient) rather than focusing solely on the branded medication. The Core Conflict The dispute highlights a fundamental tension in the weight-loss drug market. Following the FDA's declaration that the semaglutide shortage had ended, compounding pharmacies technically lost their legal justification to produce copycat versions of the drug. Yet HIMS continued marketing personalized versions of the treatment, which Novo Nordisk viewed as undermining their branded product and potentially violating regulatory requirements. This strategic misstep by HIMS reveals a deeper problem: the company appeared to prioritize its existing compounded drug business over nurturing the partnership that investors had priced as its future growth engine. The decision to continue selling personalized versions while simultaneously partnering with Novo Nordisk created an untenable conflict of interest. Valuation Reality Check The stock crash, while severe, may still not fully reflect HIMS's diminished prospects. Even after the 35% decline, HIMS trades at approximately seven times trailing revenues— more than double its five-year historical average of three times revenues. This elevated multiple made sense when investors expected the Novo Nordisk partnership to drive explosive growth, but that rationale has now evaporated. If HIMS were to revert to its historical valuation multiple of three times revenues, the stock would fall to around $25 — representing another 40% decline from current levels. This suggests the selling may not be finished, particularly as investors reassess the company's growth trajectory without its key partnership. Limited Pathway Forward HIMS can theoretically continue selling personalized obesity treatments, but this approach faces multiple headwinds. The regulatory environment remains uncertain, with the FDA potentially intervening if it determines that companies are abusing compounding loopholes rather than providing genuinely personalized medicine. The loss of Wegovy's direct sales potential also eliminates what could have been a massive revenue stream from the company's existing member base. The question now becomes whether HIMS's remaining business model can generate sufficient growth to justify any premium valuation. The company's personalized approach may serve a niche market, but it's unlikely to match the scale that direct Wegovy sales could have provided. Investment Verdict The HIMS situation represents a classic case where investors should resist the urge to "buy the dip." While the stock's 35% decline appears dramatic, the fundamental investment thesis has now been altered. The company has lost its clearest path to significant revenue growth and faces an elevated risk profile regarding regulatory compliance. For now, the prudent approach is to wait and observe how the situation develops. HIMS may find alternative pathways to growth, but without the Novo Nordisk partnership, those routes are far less certain and likely less lucrative. The market's brutal reaction to the partnership termination sends a clear message: when a company's primary growth catalyst disappears overnight, even a 35% decline may not be enough to restore attractive risk-adjusted returns. Now, regulatory risk is just a small part of the risk assessment framework we apply while constructing the 30-stock Trefis High Quality (HQ) Portfolio, which has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Yahoo
2 hours ago
- Yahoo
Eli Lilly (LLY) Retains $1,100 Price Target at Bernstein Ahead of Diabetes Conference
Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. Bernstein SocGen Group reaffirmed its Outperform rating and $1,100 price target for Eli Lilly & Company (NYSE:LLY) on June 13 ahead of the 85th Annual Meeting of the American Diabetes Association. Pixabay/Public Domain The firm outlined a number of crucial data presentations that Eli Lilly & Company (NYSE:LLY) is expected to provide at the next meeting. One of these is the full description of the ACHIEVE-1 study, which is the first phase 3 trial from the late-stage clinical program of orforglipron. Bernstein is especially keen to acquire more information on the negative event profile and discontinuation rates, even if topline data is already available. Additionally, Eli Lilly & Company (NYSE:LLY) will provide information about its muscle-wasting medication, bimagrumab. When paired with tirzepatide, this will be the first clinical data reported for an anti-muscle wasting agent used in conjunction with a GLP-1 receptor agonist, possibly hinting at future use cases. Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world's largest pharmaceutical companies. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Connectez-vous pour accéder à votre portefeuille
Business Wire
2 hours ago
- Business Wire
Zambon Announces Approval and Launch in China of the Intravenous Formulation of Fluimucil® (N-acetylcysteine)
MILAN--(BUSINESS WIRE)-- Zambon, a multinational chemical-pharmaceutical company founded on the history and values of an Italian family and committed to innovate cure and care to make patients' lives better, announces the approval by Chinese regulatory authorities and the launch on the Chinese market of the intravenous (IV) formulation of Fluimucil® (N-acetylcysteine). This milestone marks a significant step in the company's commitment to global therapeutic innovation in respiratory diseases, reflecting its dedicated focus on both clinical research and patient care. 'This approval is the result of a joint effort with local scientific communities and reinforces our commitment and sense of responsibility to improving patients' quality of life.' Share Already available in several international markets, Fluimucil® IV represents a new option for Chinese patients, where it can provide an important hospital-based therapeutic option for treating respiratory diseases characterized by excessive mucus secretion. The approval in China follows a locally conducted clinical development program, a Phase 1 and a Phase 3 clinical trial that confirmed the drug's safety, tolerability, and efficacy profile. The Phase 1 pharmacokinetics and tolerability study 1 of Fluimucil® IV in healthy volunteers, run at the Ruijin Hospital affiliated with the Shanghai Jiao Tong University School of Medicine and led by Prof. Yaozong Yuan, showed that single and multiple 600 mg doses of Fluimucil® IV were well tolerated and free from significant adverse events 2. A pivotal Phase 3 clinical trial 3 - started in June 2019 and concluded in February 2021 - involving 333 adult patients with respiratory diseases and abnormal mucus secretions across 28 hospital centers in China, and led by Prof. Jieming Qu, demonstrated that Fluimucil® IV (600 mg, twice daily) was significantly superior to placebo and non-inferior to intravenous ambroxol hydrochloride in reducing sputum viscosity and improving ease of expectoration after 7 days of treatment. The data also demonstrate that the drug is well tolerated 4. ' The approval of Fluimucil® IV in China is a major recognition of the scientific rigor with which we conducted the clinical trials and the quality of our collaboration with local research centers,' said Paola Castellani, Chief Medical Officer and Head of R&D at Zambon. ' We would like to sincerely express our gratitude to patients participating in our clinical studies, as well as to investigators for their commitment. ' ' We are proud to celebrate the 60 th anniversary of Fluimucil® by making its intravenous formulation available in China, confirming the long-standing efficacy of this molecule,' said Giovanni Magnaghi, CEO of Zambon. ' This approval is the result of a joint effort with local scientific communities and reinforces our commitment and sense of responsibility to improving patients' quality of life. ' The intravenous formulation of Fluimucil® will initially be distributed in a selection of Chinese hospitals and represents another step forward in Zambon's expansion strategy in the Chinese market.
